How does AOD-9604 differ from GLP-1 weight loss drugs
This multi-pathway profile partly explains the breadth of biological effects observed across diverse preclinical models
When BPC-157 binds to VEGFR2 receptors, it triggers a cascade that increases nitric oxide production and promotes angiogenesis, the formation of new blood vessels
The following conditions can cause absorption to be inadequate: Overgrowth of bacteria in part of the small intestine Impaired absorption (malabsorption disorders such as celiac disease or certain pancreatic disorders) Inflammatory bowel disease affecting the last part of the small intestine (IBS) Surgery that removes the part of the small intestine where vitamin B12 is absorbed Drugs such as antacids and metformin (used to treat diabetes) Repeated exposure to nitrous oxide (laughing gas) Lack of intrinsic factor Decreased stomach acidity (common among older people) Intrinsic factor may be lacking because abnormal antibodies, produced by an overactive immune system that attacks and destroys the stomach cells that produce intrinsic factor (An autoimmune reaction called autoimmune metaplastic atrophic gastritis.) Intrinsic factor may be lacking because the part of the stomach where intrinsic factor is produced was surgically removed
Dietary patterns, oxidative stress, and early inflammation: a systematic review and meta-analysis comparing Mediterranean, Vegan, and Vegetarian diets
"We simply do not have the human data to make confident recommendations about BPC-157 for GI healing," noted a 2022 editorial in Peptides reviewing the state of the field
